Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer

Annals of Surgery

Volumn 227, Issue 3, 1998, Pages 319-323

  Flanagan, Fidelma L ^a   Dehdashti, Farrokh ^a,c   Ogunbiyi, Olagunju A ^b   Kodner, Ira J ^b   Siegel, Barry A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; EARLY DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

EID: 0031912655     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199803000-00001     Document Type: Article

References (33)

1. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer. Principles and practice of oncology, 4th edition. Philadelphia: Lippincott;1993:929-977.
2. Kelly CJ, Daly JM. Colorectal cancer. Principles of postoperative follow-up. Cancer 1992;70:1397-1408.
3. Vernava AM III, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE. Current follow-up strategies after resection of colon cancer. Results of a survey of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1994;37:573-583.
4. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
5. 18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996;23:717-735.
6. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170:329-332.
7. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-382.
8. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-1670.
9. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-522.
10. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-1490.
11. Scott AM, Berlangieri SU, Zalcberg J, et al. Detection of recurrent colorectal cancer with F-18-FDG positron emission tomography (PET). J Nucl Med 1995;36:107P (abstract).
12. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992;182:549-552.
13. Xu M, Luk WK, Cutler PD, Digby WM. Local threshold for segmented attenuation correction of PET imaging of the thorax. IEEE Trans Nucl Sci 1994;41:1532-1537.
14. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-26.
15. Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 1989;124:197-200.
16. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272-277.
17. Northover J. The use of prognostic markers in surgery for colorectal cancer. Eur J Cancer 1995;31A:1207-1209.
18. Slentz K, Senagore A, Hibbert J, Mazier WP, Talbott TM. Can preoperative and postoperative CEA predict survival after colon cancer resection? Am Surgeon 1994;60:528-532.
19. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-947.
20. Northover JMA, Slack WW. A randomized, controlled trial of CEA-prompted second-look surgery in recurrent colorectal cancer; a preliminary report. Dis Colon Rectum 1984;27:576 (abstract).
21. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg K-G. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995;38:619-626.
22. Hida J, Yasutomi M, Shindoh K, et al. Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis Colon Rectum 1996;39:74-79.
23. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803-814.
24. Abdel-Nabi H, Doerr RJ. Clinical applications of indium-111-labeled monoclonal antibody imaging in colorectal cancer patients. Semin Nucl Med 1993;23:99-113.
25. Nabi HA. Radiolabeled antibodies in clinical nuclear medicine: a technology coming of age. In: Freeman LM (ed.), Nuclear Medicine Annual 1993. New York: Raven Press; 1993:1-27.
26. Neal CE, Meis LC. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer. Semin Nucl Med 1994;24:272-285.
27. Rutgers EJT. Radio-immunotargeting in colorectal carcinoma. Eur J Cancer 1995;31A:1243-1247.
28. Patt YZ, Podoloff DA, Curley S, et al. Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen. Experience with ZCE-025 and IMMU-4 monoclonal antibodies and proposed directions for clinical trials. Cancer 1993;71:4293-4297.
29. Maguire RT, Pascucci VL, Maroli AN, Gulf JV. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates. Cancer 1993;72:3453-3462.
30. Patt YZ, Podoloff DA, Curley S, et al. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 1994;12:489-495.
31. Haseman MK, Brown DW, Keeling CA, Reed NL. Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 1992;33:1750-1757.
32. Bohdiewicz PJ, Scott GC, Juni JE, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations. Clin Nucl Med 1995;20:230-236.
33. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995;36:1818-1824.